Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CACNB4 | O00305 | 3/20 | 0.31 |
| ▸ | CACNA1A | O00555 | 3/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.31 |
| ▸ | CACNG3 | O60359 | 3/20 | 0.31 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 3/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.31 |
| ▸ | CACNG7 | P62955 | 3/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17343101 | 1.00 | ALDH1A1 (0.46) | ALDH1A1TSHRCASP1BRCA1CASP7 | |
| SCHEMBL2826555 | 0.91 | ALDH1A1 (0.48) | ALDH1A1TSHRCASP1BRCA1CASP7 | |
| Mitindomide SCHEMBL19411825 | 0.83 | ALDH1A1 (0.43) | ALDH1A1TSHRCASP1BRCA1CASP7 | |
| Mitindomide SCHEMBL4171 | 0.83 | ALDH1A1 (0.43) | ALDH1A1TSHRCASP1BRCA1CASP7 | |
| SCHEMBL9527329 | 0.79 | ALDH1A1 (0.56) | ALDH1A1TSHRCASP1BRCA1CASP7 | |
| SCHEMBL9051575 | 0.79 | ALDH1A1 (0.75) | ALDH1A1POLB | |
| SCHEMBL3158529 | 0.76 | POLB (0.40) | ALDH1A1TSHRCASP1BRCA1CASP7 | |
| SCHEMBL14563304 | 0.74 | ALDH1A1 (0.41) | ALDH1A1TSHRCASP1BRCA1CASP7 | |
| SCHEMBL20043769 | 0.74 | ALDH1A1 (0.45) | ALDH1A1TSHRCASP1BRCA1CASP7 | |
| SCHEMBL22260783 | 0.74 | ALDH1A1 (0.45) | ALDH1A1TSHRCASP1BRCA1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790237-B2 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-10-17 | — | — | US | disclosed |
| US-20150361099-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| EP-0220873-B1 | Fused bicyclic imides with psychotropic activity | AMERICAN HOME PROD (US) | 1993-11-24 | — | — | EP | disclosed |
| US-4892943-A | ANTIPSYCHOTIC, ANXIOLYTIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-01-09 | — | — | US | disclosed |
| EP-0220873-A1 | Fused bicyclic imides with psychotropic activity | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361099-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | NR5A2, NR4A3, NR4A2 | ALDH1A1 1383/4885TSHR 127/4885CASP1 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.